摘要
华氏巨球蛋白血症(Waldenstr m’s macroglobulinemia,WM)/淋巴浆细胞淋巴瘤(lymphoplasmacytic lymphoma,LPL)是一种少见的惰性B细胞非霍奇金淋巴瘤,该病临床以淋巴浆细胞骨髓、脏器浸润和血清单克隆免疫球蛋白M水平升高为特点。近年来,随着免疫学、分子遗传学的发展,以及新药的不断涌现,WM/LPL的诊断与治疗取得了较大的进展,本文将对WM/LPL的诊断与治疗进行相关综述。
Waldenstr m's macroglobulinemia(WM)/lymphoplasmictic lymphoma(LPL)is a rare,incurable B-cell lymphoma.Its clinical course is characterized by elevated immunoglobulin-M(IgM)levels,lymphoplasmacytic bone marrow infiltration with cytopenia,hepatomegaly,splenomegaly,and lymphadenopathy.Recently,great progress has been made to better explain the pathobiology of WM,which has identified several clinical and genetic markers that serve prognosticate disease course and patient outcomes.This article reviews some of the recent advance with respect to prognostic markers and new treatments that are currently in progress.
作者
李丽丽
刘沁华
夏瑞祥
Li Lili;Liu Qinhua;Xia Ruixiang(Department of Hematology,the First Affiliated Hospital of Anhui Medical University,Hefei 230001,China)
出处
《临床荟萃》
CAS
2019年第6期489-495,共7页
Clinical Focus
